Curis | CRIS - Sales Revenues


Curis reported $1.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Curis USD 1.14M 1.41M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Merck USD 16.6B 310M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026
Verastem USD 18.67M 1.14M Mar/2026